Sean P Kennelly

Prof. Dr. Sean P Kennelly

orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2016 in Clinical Medicine
Verified
Journal Article
Open access
PDF file
RBRobert Briggs
Robert Briggs
SKSean P Kennelly
Sean P Kennelly
DODesmond O’nEill
Desmond O’nEill
Despite the significant public health issue that it poses, only five medical treatments have been approved for Alzheimer’s disease (AD) and these act to control symptoms rather than alter the course of the disease. Studies of potential disease-modifying therapy have generally been undertaken in patients with clinically detectable disease, yet evidence suggests that the pathological changes associated with AD begin several years before this. It is possible that pharmacological therapy may be beneficial in this pre-clinical stage before the neurodegenerative process is established. Techniques providing earlier diagnosis, such as cerebrospinal fluid biomarkers and amyloid positron emission tomography neuroimaging, are key to testing this theory in clinical trials. Recent results from trials of agents such as aducanumab are encouraging but must also be interpreted with caution. Such medicines could potentially delay the onset of dementia and would therefore markedly reduce its prevalence. However, we currently remain a good distance away from clinically available disease-modifying therapy.

3 January 2018 in European Geriatric Medicine
Verified
Journal Article
Closed access
PDF file
RBR. Briggs
R. Briggs
DCD. Carey
D. Carey
AOA. M. O’halloran
A. M. O’halloran
RKR. A. Kenny
R. A. Kenny
SKSean P Kennelly
Sean P Kennelly

28 May 2009 in Therapeutic Advances in Neurological Disorders
Verified
Journal Article
Closed access
SKSean P Kennelly
Sean P Kennelly
BLBrian A. Lawlor
Brian A. Lawlor
RKRose Anne Kenny
Rose Anne Kenny
Alzheimer's disease (AD) and vascular dementia (VaD) are important causes of cognitive decline in the elderly. As a result of an ageing population worldwide, the incidence of dementia is expected to rise exponentially over the coming decades. Vascular risk factors are implicated in the pathogenesis of both AD and VaD. Hypertension in midlife is particularly associated with an increased risk of developing dementia. One might hope the treatment of high blood pressure in midlife would reduce the risk of developing dementia, as it does the risk of stroke. Divergent results have been reported in studies examining this effect, with the evidence suggesting that certain antihypertensives confer benefits beyond others. This implies that certain drugs may have neuroprotective properties separate to their blood pressure lowering capabilities. Recent trials have added to our understanding of these relationships.

1 April 2009 in Ageing Research Reviews
Verified
Journal Article
Closed access
SKSean P Kennelly
Sean P Kennelly
BLB.A. Lawlor
B.A. Lawlor
RKR.A. Kenny
R.A. Kenny

20 April 2020 in QJM: An International Journal of Medicine
Verified
Journal Article
Open access
PDF file
AFAoife Fallon
Aoife Fallon
TDTim Dukelow
Tim Dukelow
SKSean P Kennelly
Sean P Kennelly
DODesmond O’neill
Desmond O’neill
Aoife Fallon, Tim Dukelow, Sean P Kennelly, Desmond O’Neill; COVID-19 in Nursing Homes, QJM: An International Journal of Medicine, , hcaa136, https://doi.org/1

2 August 2016 in QJM: An International Journal of Medicine
Verified
Journal Article
Open access
PDF file
RBR. Briggs
R. Briggs
ADAdam Dyer
Adam Dyer
SNS. Nabeel
S. Nabeel
RCR. Collins
R. Collins
JDJ. Doherty
J. Doherty
SKSean P Kennelly
Sean P Kennelly
Background: Studies have demonstrated that a significant minority of older persons presenting to acute hospital services are cognitively impaired; however, the impact of dementia on long-term outcomes is less clear. Aim: To evaluate the prevalence of dementia, both formally diagnosed and hitherto unrecognised in a cohort of acutely unwell older adults, as well as its impact on both immediate outcomes (length of stay and in-hospital mortality) and 12-month outcomes including readmission, institutionalisation and death. Design: Prospective observational study. Methods: 190 patients aged 70 years and over, presenting to acute hospital services underwent a detailed health assessment including cognitive assessment (standardised Mini Mental State Examination, AD8 and Confusion Assessment Method for the Intensive Care Unit). Patients or informants were contacted directly 12 months later to compile 1-year outcome data. Dementia was defined as a score of 2 or more on the AD8 screening test. Results: Dementia was present in over one-third of patients (73/190). Of these patients, 36% (26/73) had a prior documented diagnosis of dementia with the remaining undiagnosed before presentation. The composite outcome of death or readmission to hospital within the following 12 months was more likely to occur in patients with dementia (73% (53/73) vs. 58% (68/117), P = 0.043). This finding persisted after controlling for age, gender, frailty status and medical comorbidities, including stroke and heart disease. Conclusion: A diagnosis of dementia confers an increased risk of either death or further admission within the following 12 months, highlighting the need for better cognitive screening in the acute setting, as well as targeted intervention such as comprehensive geriatric assessment.